Evaluation of Gabapentin Enacarbil on Cardiac Repolarization: A Randomized, Double-Blind, Placebo- and Active-Controlled, Crossover Thorough QT/QTc Study in Healthy Adults

Clinical Therapeutics

Volumn 34, Issue 2, 2012, Pages

  Chen, Dan ^a   Lal, Ritu ^a   Zomorodi, Katie ^a   Atluri, Harisha ^a   Ho, Judy ^a   Luo, Wendy ^a   Tovera, James ^a   Bonzo, Daniel ^a   Cundy, Kenneth ^a  

^a XenoPort Inc   (United States)

Author keywords

Cardiac repolarization; Gabapentin enacarbil; QTc prolongation

Indexed keywords

GABAPENTIN ENACARBIL; MOXIFLOXACIN; PLACEBO;

ABNORMAL SENSATION; ADULT; APPLICATION SITE IRRITATION; ARTICLE; BLURRED VISION; BODY MASS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIPLOPIA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FATIGUE; FEMALE; HEART REPOLARIZATION; HUMAN; HYPESTHESIA; MALE; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; VOLUNTEER; XEROSTOMIA;

EID: 84863020739     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.01.002     Document Type: Article

References (29)

1. Horizant (gabapentin enacarbil) [prescribing information] Accessed July 13, 2011. http://us.gsk.com/products/assets/us_horizant.pdf.
2. Bogan R.K., Cramer Bornemann M.A., Kushida C.A., et al. Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study. Mayo Clin Proc 2010, 85:512-521.
3. Kushida C.A., Becker P.M., Ellenbogen A.L., et al. Randomized, double-blind, placebo-controlled trial of XP13512/GSK1838262 in patients with RLS. Neurology 2009, 72:439-446.
4. Kushida C.A., Walters A.S., Becker P., et al. A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep 2009, 32:159-168.
5. Walters A.S., Ondo W.G., Kushida C.A., et al. Gabapentin enacarbil in restless legs syndrome: A phase 2b, two-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol 2009, 32:311-320.
6. Lee D.O., Ziman R.B., Perkins A.T., et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med 2011, 7:282-292. XP053 Study Group.
7. Ellenbogen A.L., Thein S.G., Winslow D.H., et al. A 52-week study of gabapentin enacarbil in restless legs syndrome. Clin Neuropharmacol 2011, 34:8-16.
8. Neurontin (gabapentin) [prescribing information] Accessed November 30, 2010. http://www.pfizer.com/files/products/uspi_neurontin.pdf.
9. Kriel R.L., Birnbaum A.K., Cloyd J.C., et al. Failure of absorption of gabapentin after rectal administration. Epilepsia 1997, 38:1242-1244.
10. Stevenson C.M., Kim J., Fleisher D. Colonic absorption of antiepileptic agents. Epilepsia 1997, 38:63-67.
11. Cundy K.C., Sastry S., Luo W., et al. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol 2008, 48:1378-1388.
12. Stewart B.H., Kugler A.R., Thompson P.R., et al. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 1993, 10:276-281.
13. Bockbrader H.N., Breslin E.M., Underwood B.A., et al. Multiple-dose, dose-proportionality study of Neurontin (gabapentin) in healthy volunteers. Epilepsia 1996, 37. 159-159. Abstract.
14. Gidal B.E., DeCerce J., Bockbrader H.N., et al. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res 1998, 31:91-99.
15. Gidal B.E., Radulovic L.L., Kruger S., et al. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res 2000, 40:123-127.
16. McLean M.J. Clinical pharmacokinetics of gabapentin. Neurology 1994, 44(Suppl):S17-S22.
17. Cundy K.C., Annamalai T., Bu L., et al. XP13512 [(±)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther 2004, 311:324-333.
18. Cundy K.C., Branch R., Chernov-Rogan T., et al. XP13512 [(±)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther 2004, 311:315-323.
19. Lal R., Sukbuntherng J., Luo W., et al. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled, crossover study in healthy volunteers. Clin Ther 2009, 31:1776-1786.
20. Sagie A., Larson M.G., Goldberg R.J., et al. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol 1992, 70:797-801.
21. Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non antiarrhythmic drugs US Food and Drug Administration, Accessed November 30, 2010. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129357.pdf.
22. Avelox (moxifloxacin hydrochloride) [prescribing information] Accessed July 13, 2011. http://www.aveloxusa.com/pdf/Avelox_PI.pdf.
23. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects: 2004 Revision 2004, World Medical Association.
24. Chow S.C., Liu J.P. Designs of bioavailability studies. Design and Analysis of Bioavailability and Bioequivalence Studies 2000, 31-56. Marcel Dekker, Inc, New York, NY. S.C. Chow, J.P. Liu (Eds.).
25. Gibaldi M., Perrier D. Pharmacokinetics 1982, Marcel Dekker, Inc, New York.
26. Frison L., Pocock S.J. Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. Stat Med 1992, 11:1685-1704.
27. Garnett C.E., Beasley N., Bhattaram V.A., et al. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol 2008, 48:13-18.
28. Rasimas J.J., Burkhart K.K. Cardiac conduction disturbances after an overdose of nefazodone and gabapentin. Am J Emerg Med 2006, 24:886-888.
29. Lettieri J., Vargas R., Agarwal V., et al. Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers. Clin Pharmacokinet 2001, 40(Suppl 1):19-25.